1993
Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa
Guttman M, Léger G, Reches A, Evans A, Kuwabara H, Cedarbaum JM, Gjedde A. Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa. Movement Disorders 1993, 8: 298-304. PMID: 8341294, DOI: 10.1002/mds.870080308.Peer-Reviewed Original ResearchConceptsPositron emission tomographyNew COMT inhibitorL-DOPACOMT inhibitorsTreatment of patientsStriatal uptakeBrain uptakeBrain 6Cynomolgus monkeysParkinson's diseaseL-dopa analogEmission tomographyPromising agentSame animalsPET measurementsDiseaseMetabolismInhibitorsControl statePretreatmentPatientsFluorodopaAdjunctAdministrationUptake
1992
3‐O‐methyldopa administration does not alter fluorodopa transport into the brain
Guttman M, Léger G, Cedarbaum J, Reches A, Woodward W, Evans A, Diksic M, Gjedde A. 3‐O‐methyldopa administration does not alter fluorodopa transport into the brain. Annals Of Neurology 1992, 31: 638-643. PMID: 1514775, DOI: 10.1002/ana.410310611.Peer-Reviewed Original ResearchConceptsChronic L-DOPA therapyAdvanced Parkinson's diseaseL-dopa therapyPositron emission tomographic studiesL-DOPA administrationEmission tomographic studiesPositron emission tomographyL-dopa preparationsParkinsonian patientsPlasma concentrationsCynomolgus monkeysParkinson's diseasePatientsEmission tomographyL-DOPABrainTomographic studiesDiseaseAdministrationInfusionTherapyBlood
1990
The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies
Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, Cedarbaum J, Greene P, Fahn S, Rottenberg DA. The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studies. Movement Disorders 1990, 5: 203-213. PMID: 2117706, DOI: 10.1002/mds.870050304.Peer-Reviewed Original ResearchConceptsPositron emission tomographyPD patientsParkinson's diseaseScaled Subprofile ModelMetabolic anatomyFDOPA uptakeFDG/PETPositron emission tomographic studiesStriatal FDOPA uptakeTypical Parkinson's diseaseOverall disease severityEmission tomographic studiesGait disturbanceTwo-compartment modelBrain uptakePlasma radioactivityClinical measuresMetabolic asymmetryPET scansDisease processMotor asymmetryLeft-right differencesDisease severityEmission tomographySubprofile Model
1986
Effect of Supplemental Carbidopa on Bioavailability of l-Dopa.
Cedarbaum J, Kutt H, Dhar A, Watkins S, McDowell F. Effect of Supplemental Carbidopa on Bioavailability of l-Dopa. Clinical Neuropharmacology 1986, 9: 153. PMID: 3085927, DOI: 10.1097/00002826-198604000-00006.Peer-Reviewed Original ResearchMeSH KeywordsAgedBiological AvailabilityCarbidopaDihydroxyphenylalanineDrug Administration ScheduleHumansLevodopaParkinson Disease